November 8, 2024- McKesson Corporation announced results for the second quarter ended September 30, 2024.
Second Quarter Highlights:
- McKesson announced an agreement to sell its Canada-based Rexall and Well.ca retail businesses.
- Consolidated revenues of $93.7 billion increased 21%.
- Earnings per diluted share of $1.87 decreased $3.05.
- Adjusted Earnings per Diluted Share of $7.07 increased 13%.
- McKesson announced an agreement to acquire a controlling interest in Florida Cancer Specialists & Research Institute LLC’s Core Ventures.
Fiscal 2025 Outlook:
- Adjusted Earnings per Diluted Share guidance range raised to $32.40 to $33.00, from the previous range of $31.75 to $32.55.
- Fiscal 2025 Adjusted Earnings per Diluted Share guidance range indicates 18% to 20% growth compared to prior year.
- The Company does not forecast GAAP earnings per diluted share1.
Fiscal 2025 Second Quarter Result Summary
Second quarter revenues were $93.7 billion, an increase of 21% from a year ago, primarily driven by growth in the U.S. Pharmaceutical segment, which includes onboarding a new strategic partner and increased prescription volumes, including higher volumes from retail national account customers, specialty products, and GLP-1 medications.